Warning: unlink(/home/customer/www/gasiantimes.com/public_html/wp-content/temp/jnewslibrary-dEHSY7.tmp): No such file or directory in /home/customer/www/gasiantimes.com/public_html/wp-admin/includes/class-wp-filesystem-ftpext.php on line 142
Johnson & Johnson's one-shot COVID-19 vaccine effective and safe: FDA staff - Georgia Asian Times
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • Events
  • Podcasts
ABOUT
Advertise in GAT
Contact us
Thursday, March 30, 2023
Georgia Asian Times
International Insurance of Georgia
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • Events
  • Podcasts
  • Login
No Result
View All Result
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • Events
  • Podcasts
No Result
View All Result
Georgia Asian Times
No Result
View All Result
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • Events
  • Podcasts
Home Feature

Johnson & Johnson’s one-shot COVID-19 vaccine effective and safe: FDA staff

Georgia Asian Times by Georgia Asian Times
February 24, 2021
in Feature, Health

Glass Medicine Vials and hualuronic collagen and flu syringe. Tinted image.

Share on FacebookShare on Twitter

Washington DC, Feb 24, 2021 – Johnson & Johnson’s one-shot COVID-19 vaccine appeared safe and effective in trials, U.S. Food and Drug Administration (FDA) staff said in documents published on Wednesday, paving the way for its approval for emergency use.

The FDA’s panel of independent experts meets on Friday to decide whether to approve the shot. While it is not bound to follow the advice of its experts, the FDA usually does and has authorized vaccines from Pfizer and Moderna.

J&J said in documents submitted to the FDA that its data suggested its vaccine was effective at preventing asymptomatic infections. It said that in a preliminary analysis of its trial, it found 16 cases of asymptomatic cases in the placebo group versus two in the vaccine group, or an 88% efficacy rate.

While asymptomatic infection was not the primary goal of the trial, which studied the vaccine’s ability to stop moderate to severe COVID-19, the reduction of asymptomatic cases implies the shot can also cut transmission of the disease.

AD: High Museum of Atlanta

J&J’s vaccine was 66% effective in preventing COVID-19 against multiple variants in a global trial involving nearly 44,000 people, the company said last month.

Its effectiveness varied from 72% in the United States to 66% in Latin America and 57% in South Africa, where a new variant has spread, though the vaccine was 85% effective overall in stopping severe cases of the disease.

The vaccine was effective in reducing the risk of COVID-19 and preventing PCR-test confirmed COVID-19 at least 14 days after vaccination, the FDA said in its briefing documents.

Fourteen days after injection, only two vaccine recipients developed COVID-19 severe enough to need medical intervention, compared with 14 in the placebo group. After 28 days, no vaccine recipients developed COVID severe enough to require medical intervention whereas seven in the placebo group did.

Three vaccine recipients had severe side effects in the trial that were likely related to the vaccine, but the FDA said its analysis did not raise any specific safety concerns that would preclude issuance of an emergency use authorization.

The FDA said the most common solicited adverse reactions were injection site pain at 48.6%, headache at 39%, fatigue at 38.2% and myalgia at 33.2%. Other side effects included a fever in 9% of participants and a high fever in 0.2% of those who received the vaccine.

The regulator said one case of pericarditis, a heart disease, may have been caused by the vaccine. It said cases of a rare disorder, Guillain-Barre Syndrome, were unlikely to be related to the shot though data was insufficient to determine whether or not the vaccine had caused these side effects.

J&J had not previously released details of its clinical trial data beyond efficacy rates.
– Reuters

Tags: COV19Johnson & Johnsonvaccines
Previous Post

Tiger Woods awake and responsive after crash, police investigating cause

Next Post

U.S. House plans vote on COVID-19 aid bill on Friday

Georgia Asian Times

Georgia Asian Times

Related Posts

Health

What to know about new research on coffee and heart risks

March 22, 2023
Celebs tout ice baths, but science on benefits is lukewarm
Health

Celebs tout ice baths, but science on benefits is lukewarm

February 10, 2023
Health

DHS Receives Approval to Renew Simplified Process for Seniors Applying for SNAP

January 26, 2023
You’ll likely be happier if your home follows the ‘3-30-300 rule’
Health

You’ll likely be happier if your home follows the ‘3-30-300 rule’

December 22, 2022
Limited English Proficiency a Major Access Barrier to Healthcare for AAPIs, according to study
Health

Limited English Proficiency a Major Access Barrier to Healthcare for AAPIs, according to study

December 14, 2022
Hospitalizations signal rising COVID-19 risk for US seniors
Health

Hospitalizations signal rising COVID-19 risk for US seniors

December 11, 2022
Next Post

U.S. House plans vote on COVID-19 aid bill on Friday

Signup Free E-Newsletter

Upcoming Events

Apr 7
8:00 am - 3:30 pm

Symposium on Asia-USA Partnership Opportunities (SAUPO) 2023

May 6
9:00 am - 4:00 pm

GAT AAPI Summit 2023

Jul 14
6:00 pm - 10:30 pm

GAT 25 Most Influential Asian Americans in Georgia 2023

View Calendar
Logo

 

CONTACT US

Follow Us

MOST INFLUENTIAL

GAT 25 Most Influential Asian Americans Gala celebrates Asian voice

GAT 25 Most Influential Asian Americans Gala celebrates Asian voice

July 18, 2022

Video highlights of GAT 25 Most Influential Asian Americans in Georgia

July 17, 2022

2022 GAT 25 Most Influential Asian Americans in Georgia-Awards Gala

July 17, 2022

LINKS OF INTEREST

ATL Asian Film Festival

     

  • Contact Us
  • Advertise in GAT
  • About
  • Privacy Policy
  • Terms of Use

© 2023 Georgia Asian Times - Empowered by 8SOL. Managed by Arckopolis.

No Result
View All Result
  • Home
  • Metro Asian News
  • Misc Asia
  • Lifestyle
  • Business
  • Art
  • Health
  • Eat Out
  • Events
  • Podcasts

© 2023 Georgia Asian Times - Empowered by 8SOL. Managed by Arckopolis.

Welcome Back!

Sign In with Google
OR

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In

Add New Playlist

Subscribe

Stop being a headline hopper and join our FREE Newsletter service! Get exclusive access to in-depth stories and breaking news. Don’t be left out in the cold – warm up to the news with us!

    Loading
    Loading
    Loading
    Loading
    Loading
    Register for FREE to read the rest of this article, or log in to your account.

      Or Login Here :

      [loginfrm]

      Are you sure want to unlock this post?
      Unlock left : 0
      Are you sure want to cancel subscription?

      Warning: unlink(/home/customer/www/gasiantimes.com/public_html/wp-content/temp/jnewsfirstload-gGvSJv.tmp): No such file or directory in /home/customer/www/gasiantimes.com/public_html/wp-admin/includes/class-wp-filesystem-ftpext.php on line 142